Read More NASDAQ: PBYI3.48+0.30 ( 9.43% )Vol: 632,041Pricing delayed by 20 minutes. Last Updated 11/24/2021 4:00 PM Site Search Investors Home News Releases Events & Presentations Stock Information SEC Filings Analyst Coverage Resources Investor Relations Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition and development of novel therapeutics for the treatment of cancer. Corporate Overview We focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use. View all news Latest News Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib) 11/23/2021 Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting 11/20/2021 Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS) 11/19/2021 View all events Latest Events San Antonio Breast Cancer Symposium 12/07-10/2021 Society for Neuro-Oncology 2021 Annual Meeting 11/20/2021 Puma Biotechnology 3Q-2021 Financial Results Conference Call 11/04/2021 View all presentations Latest Presentation Cantor Conference Presentation Download (opens in new window) PDF 3.01 MB Quarterly Results Q3 2021 News Release Supplementary Slides (opens in new window) Form 10-Q (opens in new window) View All Results Quick Links SEC Filings Investor FAQs Information Request Form Contact Us Mariann Ohanesian Puma Biotechnology 424-248-6500 ir@pumabiotechnology.com David Schull Russo Partners, LLC david.schull@russopartnersllc.com Investor Email Alerts Sign Up Privacy Policy Legal Notice Site Map © 2021 Puma Biotechnology, Inc. - All rights reserved Powered By Q4 Inc. 5.56.0.1 (opens in new window)